<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900545</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL135</org_study_id>
    <nct_id>NCT04900545</nct_id>
  </id_info>
  <brief_title>Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients</brief_title>
  <official_title>Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Saleh Fayed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta-blockers represent a cornerstone for the treatment of coronary artery disease (CAD).&#xD;
      Their protective effect is based on the negative inotropic and chronotropic features, which&#xD;
      have been tested in a large number of randomized controlled trials, both in patients with&#xD;
      myocardial infarction (MI) and in those with stable angina, demonstrating a reduction of&#xD;
      adverse cardiovascular events, a relief of symptoms and a reduction of myocardial ischemia&#xD;
&#xD;
      However, considerable interpatient variability in response to β-blockers has been reported&#xD;
      which indicates that a considerable proportion of β-blocker-treated patients do not achieve&#xD;
      the warranted cardio protection with β- blockers. This highlights the importance of&#xD;
      identifying biomarkers associated with variability in response to β-blockers to improve the&#xD;
      current approach for β- blocker selection, which seems to be suboptimal.&#xD;
&#xD;
      This study aims to study the effect of polymorphism in adrenergic beta receptors on&#xD;
      beta-blocker response in Egyptian patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adrenergic receptors genes and blood pressure response to beta-blocker</measure>
    <time_frame>Three months</time_frame>
    <description>Investigate the association of the adrenergic receptor polymorphisms with reduction in blood pressure (expressed in units of millimeters of mercury &quot;mmHg&quot; ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adrenergic receptors genes and heart rate response to beta-blocker</measure>
    <time_frame>Three months</time_frame>
    <description>Investigate the association of the adrenergic receptor polymorphisms with reduction in heart rate (expressed as beats per minute &quot;BPM&quot; ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>beta blocker navie patients with acute coronary syndrome</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples will be collected and stored in - 80°C environment for DNA&#xD;
      extraction by DNA extraction kit according to manufacturer recommendation.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Beta-Blocker naive Egyptian patient with acute coronary syndrome.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Beta-blockers naïve patients&#xD;
&#xD;
          2. Patients been on beta-blocker therapy for at least 4 weeks.&#xD;
&#xD;
          3. Age (18-75) Years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-Egyptians.&#xD;
&#xD;
          2. Kidney failure of any stage.&#xD;
&#xD;
          3. Liver failure of any stage.&#xD;
&#xD;
          4. Malignancy.&#xD;
&#xD;
          5. Pregnancy.&#xD;
&#xD;
          6. HR &lt; 55 beats/min (in the absence of b-blocker therapy).&#xD;
&#xD;
          7. Presence of a cardiac pacemaker.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nagwa A Sabry, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ains Shams university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed A Saleh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amal A EL-Kholy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Fayed, Bsc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ains Shams university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed s Fayed, B.Sc.</last_name>
    <phone>01157677697</phone>
    <email>mohamed.saleh.mahmoud@pharma.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University Hospitals.</name>
      <address>
        <city>Cairo</city>
        <state>Al Qahirah</state>
        <zip>12234</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed sa Fayed, Bsc</last_name>
      <phone>01157677697</phone>
      <email>mohamed.saleh.mahmoud@pharma.asu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed Saleh Fayed</investigator_full_name>
    <investigator_title>Teaching assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

